<DOC>
	<DOCNO>NCT02993861</DOCNO>
	<brief_summary>The study prospective , multi-center , open-label clinical trial . Study 's purpose characterize pharmacokinetics safety four oral anti-epileptics drug ( levetiracetam , valproic acid [ divalproex sodium ER immediate release formulation inadequate enrollment } , topiramate , ocarbazepine ) non-randomized sample obese child adolescent . The study 's duration eleven day ( seven day screen four day pharmacokinetic sampling ) . Eligible participant age 2 18 year identify outpatient clinic schedule inpatient admission clinic site . Participants receive least one study drug per local standard care pharmacokinetic concentration plasma drawn accord specific dose schedule drug . Other study measure include demographic , BMI , waist/hip ratio , medical history , concomitant medication history , documentation study drug oral intake , adverse effect , physical examination . The sample size include 24 participant anti-epileptic drug ( total 96 ) .</brief_summary>
	<brief_title>Pharmacokinetics Anti-epileptic Drugs Obese Children</brief_title>
	<detailed_description />
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>2 year &lt; 18 year time enrollment BMI ≥ 95th percentile age sex , base CDC recommendation Informed consent/HIPAA parent/legal guardian assent ( applicable ) Receiving ≥ 1 study drug per local standard care Known pregnancy determine via interview test result , available</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>